News | July 29, 2011

iCad Highlights Xoft Electronic Brachytherapy System at Key Industry Conference

July 29, 2011iCAD will highlight its Xoft Axxent eBx electronic brachytherapy system at the 2011 Joint American Association of Physicists in Medicine (AAPM)/ Canadian Organization of Medical Physicists (COMP) meeting in Vancouver, British Columbia, this weekend.

At the show, iCAD will present a poster discussing dosimetry measurements for a new applicator under development for use with the Xoft system. The new interstitial applicator would enable the delivery of Xoft eBx therapy to patients who need very localized radiation delivery, such as those with spinal metastases. Authors will present at the General Poster session on Sunday, July 31 from 3:00 p.m. to 6:00 p.m. in the General Poster Area of Exhibit Hall C.

In addition, several clinicians and scientists specializing in radiation therapy and dosimetry will present information on applications for the Axxent eBx system, including its use for Intraoperative Radiation Therapy (IORT) and fundamental X-ray source calibration developments, at the “Advances in eBx” Luncheon Symposium at 12:30 p.m. on August 2, in West Wing Rooms 202-204 at the Vancouver Convention Centre.

The Axxent system uses a proprietary isotope-free miniaturized X-ray source to deliver radiation in minimally shielded environments directly to the cancerous tumor bed. The Axxent system is approved for accelerated partial breast irradiation (APBI), which can be delivered twice daily for five days, or it can be administered immediately following the lumpectomy procedure in only a few minutes with one course of therapy, also known as intraoperative radiation therapy (IORT). The system is cleared by the U.S. Food and Drug Administration (FDA) for treatment of conditions where radiation is indicated, including early stage breast cancer, skin cancer and endometrial cancer. 

iCAD recently received clearance from the FDA for its new Axxent Rigid Shield, a stainless steel shielding device to protect tissue and/or organs from radiation. The Rigid Shield is intended to be used internally, such as during IORT procedures when the treatment site is surgically exposed and provides surgeons and radiation oncologists another option for shielding patients from unnecessary radiation exposure.

In addition to the Xoft system, iCAD will also showcase its magnetic resonance imaging (MRI) suite of advanced image analysis solutions, including: VividLook, SpectraLook, OmniLook, PrecisionPoint and VersaVue Enterprise, which are designed to improve accuracy for the detection of cancers and provide clinicians with objective localization, staging, treatment planning and serial monitoring.

iCAD will be at the 2011 Joint American Association of Physicists in Medicine (AAPM)/ Canadian Organization of Medical Physicists (COMP) meeting from July 31 – August 4, 2011, in booth # 1130.

For more information:


Related Content

​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
iCAD, Xoft Axxent Electronic Brachytherapy System, eBx, 3,000 early-stage breast cancer patients, Miami Breast Cancer Conference
News | Brachytherapy Systems | March 15, 2017
CAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with intraoperative...
prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Overlay Init